Heart Failure and Renal Failure. Gerasimos Filippatos, MD, FESC, FHFA President HFA

Similar documents
ROSE-AHF and Beyond. Gerasimos Filippatos, FESC, FHFA President Heart Failure Association

Heart failure: what should be changed? Prof. Gerasimos Filippatos Attikon University Hospital

Heart Failure and Renal Disease Cardiorenal Syndrome

Pivotal Role of Renal Function in Acute Heart failure

The Cardiorenal Syndrome in Heart Failure

Overcoming the Cardiorenal Syndrome

THE KIDNEY IN HYPOTENSIVE STATES. Benita S. Padilla, M.D.

Objectives 6/14/2016. Cardiorenal Syndrome: Critical Link Between Heart and Kidney

Cardio-Renal Syndrome in Acute Heart Failure:

Cardiorenal Syndrome

Novel Approaches for Recognition and Management of Life Threatening Complications of AKI and CKD: Focus on Acute Cardiorenal Syndromes

Monitoring of Renal Function in Heart Failure

Case Presentation. This presentation is the intellectual property of the author. Contact them for permission to reprint and/or distribute.

Cardiorenal Syndrome

Cardiorenal Syndrome Prof. Dr. Bülent ALTUN Hacettepe University Faculty of Medicine Department of Internal Medicine Division of Nephrology

Cardiorenal Syndrome: What the Clinician Needs to Know. William T. Abraham, MD Director, Division of Cardiovascular Medicine

Medical Management of Acute Heart Failure

Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment

Cardiorenal Biomarkers and Heart Failure. Nicholas Wettersten, MD April 7 th, 2017

Tips & tricks on how to treat an acute heart failure patient with low cardiac output and diuretic resistance

Recognizing and Treating Patients with the Cardio-Renal Syndrome

Gerasimos Filippatos MD, FESC, FCCP, FACC

Acute heart failure syndromes: clinical challenges. Pathophysiology. ESC Congress August. Paris, France. Marco Metra

Heart-failure or Kidney Failure?

Biomarkers for optimal management of heart failure. Cardiorenal syndrome. Veli-Pekka Harjola Helsinki University Central Hospital Helsinki, Finland

The Art and Science of Diuretic therapy

Summary/Key Points Introduction

Heart Failure and Cardio-Renal Syndrome 1: Pathophysiology. Biomarkers of Renal Injury and Dysfunction

Cardiorenal syndrome. Sofie Gevaert. Ghent University Hospital, Belgium

Medical Management of Acutely Decompensated Heart Failure. William T. Abraham, MD Director, Division of Cardiovascular Medicine

Metabolic Syndrome and Chronic Kidney Disease

Pearls in Acute Heart Failure Management

Intravenous Inotropic Support an Overview

Defining and Managing the Cardiorenal Syndrome in Acute Decompensated Heart Failure. Barry M. Massie Professor of Medicine UCSF

2016 Update to Heart Failure Clinical Practice Guidelines

Cardio-renal syndrome.

How to define the target population?

The Triple Threat. Cardiac Care in the NT Annual Workshop 2017 is proudly supported by:

Management of acute decompensated heart failure and cardiogenic shock. Arintaya Phrommintikul Department of Medicine CMU

G. Allen Bryant III, M.D.,F.A.S.N Director Medical Subspecialties LMH Co-Director Renal Services LMH LMPC Chairman of Board

Pravin Manga Division of Cardiology Department of Medicine University of Witwatersrand

Οξεία καρδιακή ανεπάρκεια: Ποιες παράμετροι συμβάλλουν στη διαστρωμάτωση κινδύνου των ασθενών;

Cardiorenal and Renocardiac Syndrome

Aldosterone Antagonist. Hyd/ISDN*

Heart Failure: Guideline-Directed Management and Therapy

Hyponatremia as a Cardiovascular Biomarker

Management of Acute Heart Failure

DIAGNOSIS AND MANAGEMENT OF ACUTE HEART FAILURE

Medical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011

Update on Cardiorenal Syndrome: A Clinical Conundrum

Practical Points in Cardiorenal Syndrome

State-of-the-Art: Treatment of Renal Dysfunction in Heart Failure. W. H. Wilson Tang, MD Cleveland Clinic, U.S.A.

State of the Art: acute heart failure Is it just congestion?

Volume Control in. Wafaa El Aroussy,MD Prof of Cardiology Kasr El Aini Faculty of Medicine September 29 th, 2011

Review Article Therapeutic Options for the Management of the Cardiorenal Syndrome

Keynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes?

ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

Cardiovascular Pharmacotherapy

Hyponatremia in Heart Failure: why it is important and what should we do about it?

Management of chronic heart failure: update J. Parissis Attikon University Hospital

Biomarkers, the Kidney and the Heart: Acute Kidney Injury

ACUTE HEART FAILURE. Julie Gorchynski MD, MSc, FACEP, FAAEM. Department of Emergency Medicine Emergency Residency Program UTHSC, San Antonio TCEP 2014

Understanding the Cardio-Renal Syndromes

Doppler ultrasound, see Ultrasonography. Magnetic resonance imaging (MRI), kidney oxygenation assessment 75

WORSENING OF RENAL FUNCTION AFTER RAS INHIBITION IN DECOMPENSATED HEART FAILURE: CLINICAL IMPLICATIONS

Editorial Staying in the Pink of Health for Patients with Cardiorenal Anemia Requires a Multidisciplinary Approach

Integrating Current Knowledge into Consensus Guidelines for Acute Decompensated Heart Failure

Management of Advanced Systolic Heart Failure. Robert W. Hull MD FACC Associate Professor of Medicine West Virginia University

Inotropes for the treatment of advanced heart failure: The role of intermittent administration

Optimizing CHF Therapy: The Role of Digoxin, Diuretics, and Aldosterone Antagonists

Akash Ghai MD, FACC February 27, No Disclosures

University of Groningen. Cardiorenal interaction in heart failure Damman, Kevin

M2 TEACHING UNDERSTANDING PHARMACOLOGY

SAFETY IN THE CATH LAB How to Minimise Contrast Toxicity

Pathophysiology of Cardio-Renal Interactions

Heart failure (HF) is a chronic and progressive disease

Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF): A Randomized Clinical Trial

Heart Failure (HF) Treatment

Heart Failure Management Policy and Procedure Phase 1

Heart Failure: Combination Treatment Strategies

Acute Kidney Injury in the Hospitalized Patient

Impact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction

The Failing Heart in Primary Care

Aldosterone Antagonism in Heart Failure: Now for all Patients?

Contrast Induced Nephropathy

Congestive Heart Failure: Outpatient Management

HEART FAILURE PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

Pathophysiology of Cardio-Renal Interactions

Disclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017

Antialdosterone treatment in heart failure

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

Combination of renin-angiotensinaldosterone. how to choose?

New Advances in the Diagnosis and Management of Acute and Chronic Heart Failure

Heart Failure Pharmacotherapy An Update

Disclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17

Stages of Chronic Kidney Disease (CKD)

Estimated 5.7 million Americans with HF. 915, 000 new HF cases annually, HF incidence approaches

Definition of Congestive Heart Failure

Cardio Renal Disease. Dr. Rajasekara Chakravarthi Head, Dept of Nephrology CARE Hospitals Hyderabad

Heart Failure Guidelines For your Daily Practice

Transcription:

Heart Failure and Renal Failure Gerasimos Filippatos, MD, FESC, FHFA President HFA

Definition Epidemiology Pathophysiology Management (?)

Recommendations for NHLBI in cardiorenal interactions related to heart failure The result of interactions between the kidneys and other circulatory compartments that increase circulating volume and symptoms of heart failure and disease progression are exacerbated. At its extreme, cardio-renal dysregulation leads to what is termed cardio-renal syndrome in which therapy to relieve congestive symptoms of heart failure is limited by further decline in renal function NHLBI Working Group. Cardio-renal connections in heart failure and cardiovascular disease: executive summary. Available at: http://www.nhlbi.nih.gov/meetings/workshops/cardiorenal-hf-hd.htm.

The New Definition of Cardiorenal Syndrome Cardiorenal Syndrome (CRS) General Definition: A pathophysiologic disorder of the heart and kidneys whereby acute or chronic dysfunction in one organ may induce acute or chronic dysfunction in the other organ CRS Type I (Acute Cardiorenal Syndrome) Abrupt worsening of cardiac function (e.g. acute cardiogenic shock or decompensated congestive heart failure) leading to acute kidney injury CRS Type II (Chronic Cardiorenal Syndrome) Chronic abnormalities in cardiac function (e.g. chronic congestive heart failure) causing progressive and permanent chronic kidney disease CRS Type III (Acute Renocardiac Syndrome) Abrupt worsening of renal function (e.g. acute kidney ischaemia or glomerulonephritis) causing acute cardiac disorder (e.g. heart failure, arrhythmia, ischemia) CRS Type IV (Chronic Renocardiac Syndrome) Chronic kidney disease (e.g. chronic glomerular disease) contributing to decreased cardiac function, cardiac hypertrophy and/or increased risk of adverse cardiovascular events CRS Type V (Secondary Cardiorenal Syndrome) Systemic condition (e.g. diabetes mellitus, sepsis) causing both cardiac and renal dysfunction Ronco C. et al, EHJ 2010

The Definition Any degree of cardiac dysfunction Any degree of kidney failure Iron Deficiency Any degree of anemia What defines the above factors?

The interaction between heart failure, renal dysfunction, anaemia, and iron deficiency. Macdougall I C et al. Eur J Heart Fail 2012;14:882-886

Classification of CKD Stage Description CreatClearance (ml/min/1.73m) 1 Early renal damage, ifother Markers of this (proteinuria or Structural abnormality) >90 2 Early renal insufficiency 60-89 3 Moderate renal failure 30-59 4 Severe renal failure 15-29 5 End stage renal disease <15 US National Kidney Foundation Classification. Am J Kid Dis 2002; 39: S1-246

Filippatos G et al. Eur Heart J 2014

Definition Epidemiology Pathophysiology Management (?)

From: Braunwald s Heart Disease. 9th ed. Philadelphia, Elsevier, 2011

Prevalence of renal dysfunction 60% of patients with egfr <60 ml/min egfr, ml/min/1.73 m2 Heywood et al., J Card Fail 2007; 13:422

Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure. Results from CHARM Low LVEF Preserved LVEF Hillege et al., Circulation. 2006;113:671-678

PROPORTION OF REMAINING IN STUDY BUN and Death or HF Rehospitalization 1.0 0.9 BUN < 18 mg/dl 0.8 BUN 19-26 mg/dl 0.7 BUN 27-39 mg/dl 0.6 0.5 Log-Rank Test P-Value = 0.0005 BUN > 40 mg/dl 0 10 20 30 40 50 60 70 DAYS IN STUDY Filippatos G et al.j Cardiac Failure 2007

Determinants and forms of worsening renal function in heart failure. Filippatos G et al. Eur Heart J 2013;eurheartj.eht515

Definition Epidemiology Pathophysiology Management (?)

cardiac output Hypotension Cardiac dysfunction systemic venous pressure ACEi/ ARBs Neurohormonal activation Renal hypoperfusion Renal dysfunction i.v. Furosemide Adenosine release Tubuloglomerular feedback Renal venous pressure Metra, Brutsaert, Dei Cas, Gheorghiade. IACC ESC Textbook, 2011

cardiac output Hypotension Cardiac dysfunction systemic venous pressure ACEi/ ARBs Neurohormonal activation Renal hypoperfusion Renal dysfunction i.v. Furosemide Adenosine release Tubuloglomerular feedback Renal venous pressure Metra, Brutsaert, Dei Cas, Gheorghiade. IACC ESC Textbook, 2011

Emerging Therapies in HF De Luca L, Mebazaa A, Filippatos G et al. Eur J Heart Fail 2008 Blocks adenosine mediated afferent arteriole vasoconstriction maintains GFR Inhibits reabsorption of sodium and water in the proximal tubule diuresis

MECHANISMS OF DISEASE PROGRESSION DRUG TOXICITY Cardiac and Renal Injury Cell death by necrosis and apoptosis Tn Release Fibrosis Progression of Heart and Kidney Failure RAAS Neurohormonal Activation Hemodynamic Deterioration Modified from Filippatos G et al. Am J Physiol 1999

Early drop in systolic blood pressure and worsening renal function in AHF: renal results of Pre RELAX AHF European Journal of Heart Failure vol 13, pages 961-967, 2014 DOI: 10.1093/eurjhf/hfr060

Early drop in systolic blood pressure and worsening renal function in AHF: renal results of Pre RELAX AHF European Journal of Heart Failure vol 13, pages 961-967, 2014 DOI: 10.1093/eurjhf/hfr060

Potential pathogenetic pathways linking heart failure with renal dysfunction. Filippatos G et al. Eur Heart J 2014

Definition Epidemiology Pathophysiology Management (?)

Heart Failure Drug Treatment Options Symptom Relieving Disease Modifying Diuretics Digoxin ACE inhibitors /angiotensin II receptor antagonists Beta-blockers Aldosterone receptor antagonists

Selected Placebo-Controlled Trials in Patients with Heart Failure: Renal Function of Participants and Medication Efficacy Shlipak, M. G. Ann Intern Med 2003;138:917-924

Treatment algorithm for patients with systolic heart failure, based on renal function Shlipak, M. G. Ann Intern Med 2003;138:917-924

ACE-I associated creatinine elevations Bakris GL et al. Arch Int Med 2000;160:685

Decompensated chronic HF Consider higher dose of diuretics in renal dysfunction or with chronic diuretic use. ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

What to do next? 1. Increase furosemide dose 2. Ιntravenous infusion rather than bolus therapy 3. Substitution of an ineffective loop diuretic for another one 4. Add metolazone and/ or potasium sparing diuretic 5. Add dopamine at 2-5 mcg/k/m 6. Withdraw b-blocker and/ or ACE inhibitor 7. Add dobutamine 8. Add levosimendan 9. Start ultrafiltration 10. Start dialysis 11. Insert IABP 12. Insert another device Maisel A, Filippatos G, Heart Failure. Publisher Jaypoor Brothers, 2014

Renal Replacement Therapy I IIa IIb III Ultrafiltration may be considered for patients with obvious volume overload to alleviate congestive symptoms and fluid weight. I IIa IIb III Ultrafiltration may be considered for patients with refractory congestion not responding to medical therapy.

Acute Kidney Injury Timeline

Cardiorenal Interaction: The Future We need to use meaningful definitions and validate them in different clinical settings. We need to evaluate the impact of early biomarkers on diagnosis and various therapeutic approaches We need to appraise current evidence and generate wise recommendations for practice. We need research to generate the missing evidence.